Trial Evaluating the Efficacy of Pimavanserin, a Selective Serotonin 5-HydroxyTryptamine-2A (5HT2A) Inverse Agonist, to Treat Impulse Control Disorders in Parkinson's Disease.
Clinical trial NCT06754553 · NOT_YET_RECRUITING
Trial details
- NCT number
- NCT06754553
- Sponsor
- University Hospital, Strasbourg, France
- Status
- NOT_YET_RECRUITING
- Study type
- OBSERVATIONAL
- Start date
- 2025-02-01
- Primary completion
- 2026-02-01
- Enrollment
- 100
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.